Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Short term Debt: 2020-2022

Historic Short term Debt for Mereo BioPharma Group (MREO) over the last 2 years, with Dec 2022 value amounting to $486,000.

  • Mereo BioPharma Group's Short term Debt was N/A to $486,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $486,000, marking a year-over-year change of. This contributed to the annual value of $486,000 for FY2022, which is N/A change from last year.
  • Latest data reveals that Mereo BioPharma Group reported Short term Debt of $486,000 as of FY2022, which was down 9.46% from $536,773 recorded in FY2020.
  • Over the past 5 years, Mereo BioPharma Group's Short term Debt peaked at $536,773 during FY2020, and registered a low of $486,000 during FY2022.
  • Moreover, its 2-year median value for Short term Debt was $511,387 (2020), whereas its average is $511,387.